Biotech Values

[DewDiligence]

(MNTA)—TEVA excerpt re FoBs from 11/18/25 Jefferies webcast (time point 32:15)…

Q: (Dave Steinberg, Jefferies analyst): Does Teva have designs on being a major player in biosimilars?… You didn’t get the AMGN partnership from AGN [i.e. AGN is retaining the AMGN FoB partnership (originally formed with Watson) rather than including it in the generic-drug business being sold to TEVA]. So how do you catch up?

A: (Eyal Desheh, CFO): Inorganically [i.e. via one or more acquisitions].

--
MNTA has told investors it expects to ink a broad* FoB partnership deal imminently. Is it crazy to imagine that archenemies TEVA and MNTA could become partners?

*MNTA’s FoB partnership with BXLT remains active with a single program for Humira.